Key Developments for Novartis in the Past Month
As discussed earlier, Novartis’s (NVS) operating revenue grew 4% year-over-year in the first quarter, to ~$12.7 billion from ~$11.5 billion. The chart below shows recent developments for Novartis. On May 30, the FDA accepted Novartis’s supplemental new drug application for the drug Promacta, and granted priority review designation to Promacta in combination with standard immunosuppressive therapy as a first-line treatment for severe aplastic anemia.